Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain [Yahoo! Finance]
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]